Puerperal mastitis: A reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk

Cancer Causes and Control

Volumn 24, Issue 11, 2013, Pages 1911-1923

  Cramer, Daniel W ^a,b   Williams, Kristina ^b   Vitonis, Allison F ^a   Yamamoto, Hidemi S ^a   Stuebe, Alison ^c   Welch, William R ^a   Titus, Linda ^d   Fichorova, Raina N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

CA125; CA15.3; Ovarian cancer; Puerperal mastitis

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; IMMUNOGLOBULIN G1; MUCIN 1;

ADULT; ANTIBODY DETECTION; ARTICLE; BREAST FEEDING; CANCER RISK; CASE CONTROL STUDY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MASTITIS; OVARY CARCINOMA; PARITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PUERPERAL DISORDER; PUERPERAL MASTITIS; RISK REDUCTION; SELF REPORT; UNITED STATES;

ADULT; ANTIBODIES; BREAST FEEDING; CA-125 ANTIGEN; CASE-CONTROL STUDIES; COMORBIDITY; ELECTROCHEMICAL TECHNIQUES; FEMALE; HUMANS; LOGISTIC MODELS; LUMINESCENT MEASUREMENTS; MASTITIS; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN-1; MUCINS; NEW ENGLAND; OVARIAN NEOPLASMS; PARITY; PREGNANCY; PUERPERAL DISORDERS; RISK FACTORS; YOUNG ADULT;

EID: 84886804752     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0266-1     Document Type: Article

References (32)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al (2012) SEER cancer statistics review, 1975-2009 (vintage 2009 populations). National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site
2. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK et al (1979) "Incessant ovulation" and ovarian cancer. Lancet 2:170-173
3. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270:2813-2818
4. Langseth H, Hankinson SE, Siemiatycki J, Weiderpass E (2008) Perineal use of talc and risk of ovarian cancer. J Epidemiol Commun Health 62:358-360
5. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385-394
6. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:1125-1131
7. Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR et al (2010) Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 19:1595-1601
8. Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN et al (2010) Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control 21:1193-1201
9. Vitonis AF, Titus-Ernstoff L, Cramer DW (2011) Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol 117:1042-1050
10. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A et al (2010) Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol 119:462-468
11. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, et al (2008) Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 80:4741-4751 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=18484740
12. Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167:653-666
13. Foxman B, D'Arcy H, Gillespie B, Bobo JK, Schwartz K (2002) Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol 155:103-114
14. Jonsson S, Pulkkinen MO (1994) Mastitis today: incidence, prevention and treatment. Ann Chir Gynaecol Suppl 208:84-87
15. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL et al (2013) Obesity and risk of ovarian cancer subtypes: evidence from the ovarian cancer association consortium. Endocr Relat Cancer 20:251-262
16. Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control 23:919-927
17. Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L et al (1986) Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 77:689-696
18. Lambe M, Johansson AL, Altman D, Eloranta S (2009) Mastitis and the risk of breast cancer. Epidemiology 20:747-751
19. Stafford I, Hernandez J, Laibl V, Sheffield J, Roberts S et al (2008) Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 112:533-537
20. Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52:1954-1960
21. Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69:1-11
22. Jerome KR, Kirk AD, Pecher G, Ferguson WW, Finn OJ (1997) A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol Immunother 43:355-360
23. Gunther J, Petzl W, Zerbe H, Schuberth HJ, Koczan D et al (2012) Lipopolysaccharide priming enhances expression of effectors of immune defence while decreasing expression of pro-inflammatory cytokines in mammary epithelia cells from cows. BMC Genomics 13:17
24. Hardardottir H, Parmley TH 2nd, Quirk JG Jr, Sanders MM, Miller FC et al (1990) Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol 163:1925-1931
25. Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M et al (2012) Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med 10:86
26. Sarandakou A, Protonotariou E, Rizos D (2007) Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 44:151-178
27. Hammer JF, Morton JM, Kerrisk KL (2012) Quarter-milking-, quarter-, udder- and lactation-level risk factors and indicators for clinical mastitis during lactation in pasture-fed dairy cows managed in an automatic milking system. Aust Vet J 90:167-174
28. Ryan AS, Wenjun Z, Acosta A (2002) Breastfeeding continues to increase into the new millennium. Pediatrics 110:1103-1109
29. Sjovall K, Nilsson B, Einhorn N (2002) The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 85:175-178
30. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S et al (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61:697-716
31. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574-583
32. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ et al (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934-938